New diabetes clinical trial: Semaglutide in Nonalcoholic Fatty Liver Disease
Published on: April 14, 2023 at 11:00AM
Condition: Non-alcoholic Fatty Liver Disease
Interventions: Drug: Rybelsus Oral Product; Drug: Ozempic Injectable Product; Drug: Tocopherol and/or Actos
Sponsor: Zagazig University
Recruiting
https://ift.tt/p8VnT5e
Condition: Non-alcoholic Fatty Liver Disease
Interventions: Drug: Rybelsus Oral Product; Drug: Ozempic Injectable Product; Drug: Tocopherol and/or Actos
Sponsor: Zagazig University
Recruiting
https://ift.tt/p8VnT5e
Comments
Post a Comment